Dr. Tolaney on the ATEMPT Trial for HER2+ Breast Cancer

Sara M. Tolaney, MD, MPH
Published Online: Wednesday, Nov 08, 2017



Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the ATEMPT trial for patients with HER2-positive breast cancer.

This trial investigated patients with stage I HER2-positive disease following the APT trial, states Tolaney. The aim of the study was to determine if using T-DM1 (ado-trastuzumab emtansine; Kadcyla) is a beneficial approach.

The trial randomized patients to a year of T-DM1 or paclitaxel and trastuzumab (Herceptin). It was designed to compare the clinically relevant toxicities seen between the 2 arms and establish a 3-year disease-free survival in the T-DM1 arm. The trial has completed accrual and results are expected 2019, explains Tolaney.
 


Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the ATEMPT trial for patients with HER2-positive breast cancer.

This trial investigated patients with stage I HER2-positive disease following the APT trial, states Tolaney. The aim of the study was to determine if using T-DM1 (ado-trastuzumab emtansine; Kadcyla) is a beneficial approach.

The trial randomized patients to a year of T-DM1 or paclitaxel and trastuzumab (Herceptin). It was designed to compare the clinically relevant toxicities seen between the 2 arms and establish a 3-year disease-free survival in the T-DM1 arm. The trial has completed accrual and results are expected 2019, explains Tolaney.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Leveraging New Evidence in the Context of Evolving Early-Stage Treatment Standards in HER2-Positive Breast CancerJan 30, 20181.5
14th Annual School of Breast Oncology® OnlineFeb 10, 201825
Publication Bottom Border
Border Publication
x